Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCW9207
- Development stage
- Preclinical
- Lead developer
- HCW Biologics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Ex Vivo
01
Overview
HCW9207 is an investigational **heteromeric fusion protein complex** developed by **HCW Biologics** using its TOBI platform to generate a multifunctional cytokine biologic for **ex vivo priming of memory-like natural killer cells** in adoptive cell therapy. The construct is composed of two recombinant fusion proteins: one containing **IL-18**, **IL-15**, and the extracellular domain of **human tissue factor**; the other containing **single-chain IL-12**, the soluble **IL-15 receptor alpha** domain, and an **anti-CD16 single-chain variable fragment**. By co-delivering signaling through **IL-12**, **IL-15**, **IL-18**, and **CD16**, HCW9207 is designed to replace the conventional IL-12/IL-15/IL-18 cytokine cocktail used for NK-cell memory-like priming, with the goal of improving manufacturability, standardization, and immune activation for **cell-based cancer therapy**.
- Other names
- HCW9207HCW-9207HCW 9207
02
Targets
FCGR3B (Fc gamma receptor III)IL-12R (Interleukin-12 receptor)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL-18R (Interleukin-18 receptor complex)
Beyond the preview
Go deeper on HCW9207.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCW9207.